In glioblastoma, phosphatidylinositol 3-kinase (PI3K) signaling is frequently activated by loss of the tumor suppressor phosphatase and tensin homolog (PTEN) 1 . However, it is not known whether inhibiting PI3K represents a selective and effective approach for treatment. We interrogated large databases and found that sonic hedgehog (SHH) signaling is activated in PTEN-deficient glioblastoma. We demonstrate that the SHH and PI3K pathways synergize to promote tumor growth and viability in human PTEN-deficient glioblastomas. A combination of PI3K and SHH signaling inhibitors not only suppressed the activation of both pathways but also abrogated S6 kinase (S6K) signaling. Accordingly, targeting both pathways simultaneously resulted in mitotic catastrophe and tumor apoptosis and markedly reduced the growth of PTENdeficient glioblastomas in vitro and in vivo. The drugs tested here appear to be safe in humans; therefore, this combination may provide a new targeted treatment for glioblastoma.
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. Currently, the average time from diagnosis to death is 15-18 months 2 , and therefore new treatment approaches are needed 3 . 36% of GBMs harbor loss or inactivation of PTEN 1 , a lipid phosphatase that is a key negative regulator of PI3K signaling. However, it is unclear whether tumors deficient for PTEN are susceptible to PI3K inhibitors 4, 5 .
Here we describe a therapeutic approach that targets PTENdeficient GBMs. In two large data sets, PTEN mRNA expression varies more than tenfold among GBMs 6 . We divided a data set of 100 GBMs 6 and The Cancer Genome Atlas (TCGA) data set of over 400 GBMs 7 into two groups: GBMs that express low levels of PTEN and all other tumors (Supplementary Fig. 1a ). In both data sets, GBMs with decreased PTEN expression exhibited increased SHH pathway activation, as assessed by expression of Gli1 and Gli2, which encode transcription factors that are critical for SHH signaling ( Fig. 1a and Supplementary Fig. 1b) . Moreover, PTEN expression negatively correlated with the combined mRNA expression of GLI1 and GLI2 across each data set (Spearman correlation coefficient, −0.23 and P = 0.02 for the data set of 100 GBMs and Spearman correlation coefficient, −0.23226 and P = 2 × 10 −6 for the TCGA data set). Further analysis of the TCGA data demonstrated that GLI2 expression was higher in tumors with PTEN copy loss ( Fig. 1b and Supplementary Fig. 1c) , and PTEN expression correlated with PTEN copy number. These data indicate that PTEN-deficient GBMs exhibit activation of SHH signaling in addition to the known activation of PI3K cascades.
We tested the effects of selective PI3K and SHH inhibitors on neurosphere cultures from a human PTEN-deficient GBM (hBT70) and a PTEN-expressing GBM (hBT75) 8 (Fig. 1d) . Neurosphere cultures recapitulate critical features of primary tumors, including somatic mutations, antigenic properties, tumor initiation and angiogenic activity 9 . Treatment with the PI3K inhibitor NVP-BKM120 (ref. 4) at 100 nM (half-maximum inhibitory concentrations (IC 50 ) of 52, 166 and 116 nM for p110α (PIK3CA), p110β (PIK3CB) and p110γ (PIK3CG), respectively) 5 did not alter the cell viability of PTENdeficient or PTEN-expressing neurospheres (Fig. 1c,d) . We saw no effect on viability when we treated the neurospheres with NVP-LDE225, an inhibitor of smoothened (SMO), which prevents SHH signaling 10 . In contrast, in PTEN-deficient GBM neurosphere cultures only, we found a significant reduction in viability with a combination Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities of NVP-BKM120 and NVP-LDE225 at multiple doses of each inhibitor; we observed responses to each of the PI3K inhibitors alone at high doses (Fig. 1d,e and Supplementary Fig. 1d ). Using varying doses of several inhibitors targeting the PI3K and SHH pathways 11 , we consistently observed a synergistic decrease in cell viability with combination therapy (Fig. 1e and Supplementary Fig. 1e,f) . We saw this effect only with continuous treatment (Supplementary Fig. 1g) . Thus, simultaneous inhibition of the PI3K and SHH pathways reduces the viability of human PTEN-deficient GBMs, as demonstrated using several distinct targeted drugs.
We analyzed responses to combination therapy in monolayer cultures of hBT70 and two additional PTEN-deficient tumors (hBT112 and hBT145) (Fig. 1c) 12 . Combination therapy led to an efficacious and synergistic reduction in viability in all of the PTEN-deficient tumors tested (Fig. 1f) (two-way analysis of variance (ANOVA) factorial interaction, F = 10.27, DFn = 1, DFd = 8, P = 0.0125) but did not alter the growth of PTEN-expressing GBMs (Fig. 1c,g ). As human GBMs vary in several additional characteristics ( Supplementary  Fig. 1h ), we asked whether PTEN expression is a critical determinant of viability response. Two different shRNAs against PTEN introduced shControl, nonspecific control shRNA; shPTEN1, one shRNA specific to PTEN; shPTEN2, a second shRNA specific to PTEN. (i) PTEN, GLI1 andGLI2 mRNA levels normalized to those of GAPDH, with results for each treatment normalized to those of the group not treated with virus. *P < 0.05, **P < 0.01, ***P < 0.005, † P = 0.06. n = 8 independent experiments for hBT188 in the top graph. For shControl, P = 0.36 for PTEN, P = 0.72 for GLI1, and P = 0.20 for GLI2; for shPTEN1, P = 0.03 for PTEN, P = 1.1 × 10 −12 for GLI1, and P = 0.0004 for GLI2; for shPTEN2, P = 0.03 for PTEN, P = 0.0003 for GLI1, and P = 9 × 10 −6 for GLI2. n = 6 independent experiments for hBT239 cells in the bottom graph. For shControl, P = 1.3 for PTEN, P = 1.1 for GLI1, and P = 2.72 for GLI2; for shPTEN1, P = 0.03 for PTEN, P = 0.0002 for GLI1, and P = 0.008 for GLI2; for shPTEN2, P = 0.03 for PTEN, P = 4.3 × 10 −14 for GLI1, and P = 0.06 for GLI2. Statistical analyses in i were performed using Z-test with Bonferroni post test. (j) GBM responses to therapies after PTEN knockdown in hBT188 cells (n = 10 repeats, with two technical replicates in each of five experiments; shPTEN1: *F = 4.69, DFn = 6, DFd = 81, P = 0.004; shPTEN2: *F = 3.10, DFn = 6, DFd = 81, P = 0.008) or hBT239 cells (n = 9 repeats with three technical replicates in three experiments; shPTEN1: *F = 2.59, DFn = 6, DFd = 72, P = 0.02; shPTEN2: *F = 2.47, DFn = 6, DFd = 72, P = 0.03). All error bars throughout the figure represent the s.e.m.
in two distinct PTEN-expressing human GBMs decreased PTEN expression by 50-70% (Fig. 1h) . Acute reduction of PTEN expression increased the expression of GLI1 and GLI2 (Fig. 1i) , whereas acute overexpression of PTEN decreased the expression of these SHH pathway components (Supplementary Fig. 1i) . Notably, when PTEN expression was stably reduced in two distinct GBM tumors, combination therapy with NVP-BKM120 and NVP-LDE225 decreased the viability of previously resistant cells (Fig. 1j) . Thus, PTEN expression is not merely correlative for response but has a causative role as well.
On the basis of these promising results, we analyzed PTEN-deficient tumors in vivo using an orthotopic xenograft model 13 . We intracranially injected 1 × 10 6 human GBM cells (hBT112) expressing luciferase into nu/nu mice and then monitored tumor size with bioluminescence 13 . We initiated treatment only after tumors showed exponential growth. Mice treated with vehicle or NVP-LDE225 exhibited rapid increases in bioluminescence (Fig. 2a) . NVP-BKM120 treatment initially slowed tumor growth, but this effect was transient. In contrast, mice treated with combination therapy showed stable bioluminescence throughout the experiment, indicating substantially reduced tumor growth (P = 0.026 compared to vehicle treatment) (Fig. 2a) .
We obtained similar results in a second tumor tested in vivo (hBT145) (Fig. 2b) . Moreover, whereas the groups treated with NVP-BKM120 or the combination therapy showed improved survival compared to the vehicle-treated and NVP-LDE225-treated groups (Fig. 2c) , the tumor burden in animals that survived more than 4 months was reduced in mice treated with the combination therapy (Fig. 2d) .
Consistent with the results from the bioluminescence studies, magnetic resonance imaging (MRI) analyses and histological examinations showed that combination therapy diminished tumor sizes (Fig. 2e,f ) and decreased the dissemination of tumor cells (Fig. 2f) , as assessed by staining for human nuclear mitotic apparatus protein (NUMA).
To examine the cellular basis for the synergistic effects of the combination treatment, we labeled glioblastoma cells with DiI (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate) and imaged individual cells over time (Fig. 3a) . Combination therapy decreased proliferation and increased cell death (Fig. 3b) . Accordingly, combination therapy increased apoptosis both in vitro, as demonstrated by activated caspase-3 (Fig. 3c,d and Supplementary  Fig. 2a) , and in vivo, as demonstrated by TUNEL staining of GBM xenografts (Fig. 3e,f) . Combination therapy also affected tumor cell Fig. 2b ) and resulted in abnormal mitotic spindles in which chromosomes distributed in a rosettelike pattern surrounded centrally located centrosomes (Fig. 3g,h) . In vivo, combination therapy-treated GBM cells appeared smaller in size, with frequent pyknotic nuclei and aberrant mitotic figures (Fig. 3i and  Supplementary Fig. 2c ). Mitotic abnormalities might engender mitotic catastrophe 14 , thereby contributing to diminished tumor growth. Indeed, with combination therapy, many dividing cells produced two daughters that rapidly died (Supplementary Fig. 2d) . Thus, combination treatment causes mitotic abnormalities and apoptosis in vitro and in vivo.
Combination therapy clearly achieves targeted responses: NVP-BKM120, either alone or combined with NVP-LDE225, decreased the phosphorylation of AKT (pAKT), which is the kinase that is activated by PIP3 phospholipids 15 (Fig. 4a and Supplementary Fig. 3a) . Consistent with data that GLI expression is high in PTEN-deficient GBMs, GLI1 mRNA was readily detectible in hBT112 cells, and NVP-LDE225 decreased the expression of GLI1 and PTC1 (Fig. 4b) . This effect of NVP-LDE225 was potentiated when combined with NVP-BKM120 ( Fig. 4c and Supplementary Fig. 3b ).
An inhibitor of the PI3K-regulated mTOR complex (NVP-RAD001) 16 significantly reduced tumor cell viability when combined with NVP-LDE225 (Fig. 4d) , indicating that the pathways intersect further downstream. Inhibition of S6K, which is regulated by mTOR, could explain the decreased cell size observed with the combination therapy 15, 17 . In cultured GBM cells, treatment with either NVP-BKM120 or NVP-LDE225 alone reduced the amounts of phosphorylated S6K (pS6K) and phosphorylated S6 (pS6), and these effects were potentiated with combination therapy (Fig. 4e and Supplementary  Fig. 3c) . Similarly, in vivo, both NVP-LDE225 and the combination treatment reduced the amounts of pS6 (Fig. 4f,g ). Stimulation of GBM cells with SAG, a SMO agonist 18 , caused dose-dependent increases in the amounts of pS6, implicating the SHH pathway in S6K activation (Fig. 4h) . Furthermore, a small-molecule inhibitor of S6K (PF-4708671) 19 led to dose-dependent decreases in the amounts of pS6 and tumor cell viability ( Fig. 4i and Supplementary Fig. 3d ), suggesting that S6K is a critical interaction node for the combination therapy. Combination therapy also synergistically decreased expression of cyclin D1 (CCND1), which is regulated by the PI3K, SHH and S6K pathways 20, 21 ( Supplementary Fig. 3e) . Thus, although NVP-BKM120 and NVP-LDE225 each successfully attack appropriate targets in PTEN-deficient GBM cells, both PI3K and SHH signaling must be targeted to maximally diminish S6K activity and repress tumor growth.
To identify additional consequences of the combination therapy on a genome-wide scale, we used Affymetrix microarrays with two different PTEN-deficient GBMs treated with either single drugs or the combination therapy. Genes markedly affected by the combination therapy in hBT70 tumors, hBT112 tumors or both ( Supplementary  Fig. 3f and Supplementary Table 1) included several genes that are implicated in GBM prognosis or have been identified as targets of the SHH, PI3K or S6 pathways [22] [23] [24] (Fig. 4j) .
The studies presented here indicate that SHH signaling and PI3K cascades are both activated in PTEN-deficient GBMs, and therapies that target only PI3K have limited efficacy in these tumors 25 . Instead, a combination of PI3K and SHH signaling inhibitors successfully targets both pathways and achieves a synergistic effect on S6K signaling. Combination therapy causes apoptosis as well as mitotic catastrophe and substantially reduces tumor growth in vitro and in vivo.
Activation of SHH signaling has been reported previously in GBMs 26, 27 . Here we found that expression of GLI transcription factors correlates with both PTEN mRNA levels and PTEN copy number in large GBM databases. Our data indicate a causal connection between PTEN and SHH signaling and identify S6K signaling as a critical node of interaction [28] [29] [30] [31] (Fig. 4j) . In the absence of PTEN, decreased degradation of PIP3 lipids results in activation of AKT, mTOR and S6K; S6K activity in turn enhances GLI-dependent transcription 17, [32] [33] [34] . Stimulation of the SHH receptor, SMO, further enhances S6K signaling. Accordingly, PTEN deficiency increases PI3K, SHH and S6K signaling, and thus a combination of PI3K and SHH inhibitors results in apoptotic death of PTEN-deficient GBM cells. 
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Previous studies have suggested that high doses of inhibitors of either the SHH or PI3K pathway reduce GBM neurosphere growth, colony formation or both 4, [35] [36] [37] [38] . Here we show efficacy using doses of the PI3K inhibitor NVP-BKM120 and the SHH pathway inhibitor NVP-LDE225 that are achievable in vivo through oral administration. These drugs cross the blood-brain barrier, have acceptable toxicity profiles and have now entered clinical trials 5, 39 (NCT01576666 at clinicaltrials.gov). Our results indicate the need to monitor PTEN status and pS6K activation in clinical studies and highlight the importance of testing these agents as a combination therapy for glioblastoma 39 (NCT01576666 at clinicaltrials.gov).
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